Moderna receives fda authorization for emergency use of omicron-targeting bivalent covid-19 booster vaccine for adults 18 years and older

Moderna's bivalent booster shots to be available nationwide in coming days mrna-1273.222 targets ba.4/.5 strains of omicron variant cambridge, ma / accesswire / august 31, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has received emergency use authorization (eua) from the u.s. food and drug administration (fda) for its ba.4/.5 omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.222. authorization has been given for a 50 Μg booster dose for adults over 18 years of age who have received either a primary series or an initial booster of any of the authorized or approved covid-19 vaccines.
MRNA Ratings Summary
MRNA Quant Ranking